R1 Therapeutics to present Phase 2b trial-in-progress poster for AP306 at ASN Kidney Week 2026
-
Poster will outline the design of R1’s ongoing global Phase 2b trial evaluating AP306 in patients with hyperphosphatemia
-
AP306 is a potential first-in-class, oral, non-binder small molecule designed to inhibit all three intestinal phosphate transporters
-
Phase 2b trial is enrolling across the US and China, with topline data expected in H1 2027
Redwood City, California – 15 October 2026 – R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, today announced the presentation of a trial-in-progress poster highlighting its ongoing global Phase 2b study of AP306 at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 21–25, 2026, in Denver, Colorado.
